{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:07:22Z","timestamp":1783426042572,"version":"3.54.6"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research Council of Norway through its Centers of Excellence","award":["237718"],"award-info":[{"award-number":["237718"]}]},{"name":"Research Council of Norway through its Centers of Excellence","award":["262652"],"award-info":[{"award-number":["262652"]}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2019096"],"award-info":[{"award-number":["2019096"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The effect of cancer therapies is often tested pre-clinically via in vitro experiments, where the post-treatment viability of the cancer cell population is measured through assays estimating the number of viable cells. In this way, large libraries of compounds can be tested, comparing the efficacy of each treatment. Drug interaction studies focus on the quantification of the additional effect encountered when two drugs are combined, as opposed to using the treatments separately. In the bayesynergy R package, we implement a probabilistic approach for the description of the drug combination experiment, where the observed dose response curve is modelled as a sum of the expected response under a zero-interaction model and an additional interaction effect (synergistic or antagonistic). Although the model formulation makes use of the Bliss independence assumption, we note that the posterior estimates of the dose\u2013response surface can also be used to extract synergy scores based on other reference models, which we illustrate for the Highest Single Agent model. The interaction is modelled in a flexible manner, using a Gaussian process formulation. Since the proposed approach is based on a statistical model, it allows the natural inclusion of replicates, handles missing data and uneven concentration grids, and provides uncertainty quantification around the results. The model is implemented in the open-source Stan programming language providing a computationally efficient sampler, a fast approximation of the posterior through variational inference, and features parallel processing for working with large drug combination screens.<\/jats:p>","DOI":"10.1093\/bib\/bbab251","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T15:11:05Z","timestamp":1623683465000},"source":"Crossref","is-referenced-by-count":20,"title":["bayesynergy: flexible Bayesian modelling of synergistic interaction effects in\n                    <i>in vitro<\/i>\n                    drug combination experiments"],"prefix":"10.1093","volume":"22","author":[{"given":"Leiv","family":"R\u00f8nneberg","sequence":"first","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cremaschi","sequence":"additional","affiliation":[{"name":"Singapore Institute for Clinical Sciences (SICS), A*STAR, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hanes","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo 0379, Norway"},{"name":"Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit M","family":"Enserink","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo 0379, Norway"},{"name":"Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1066 Blindern, Oslo 0316, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zucknick","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"2021110815081372100_ref1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01952257","article-title":"Uber Kombinationswirkungen","volume":"114","author":"Loewe","year":"1926","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"issue":"3","key":"2021110815081372100_ref2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"2","key":"2021110815081372100_ref3","first-page":"331","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2021110815081372100_ref4","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Fouquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"2021110815081372100_ref5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst"},{"issue":"W1","key":"2021110815081372100_ref6","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"2021110815081372100_ref7","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"12","key":"2021110815081372100_ref8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat Mach Intell"},{"key":"2021110815081372100_ref9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLOS ONE"},{"key":"2021110815081372100_ref10","first-page":"351","volume-title":"Methods for High-Throughput Drug Combination Screening and Synergy Scoring","author":"He","year":"2018"},{"issue":"1","key":"2021110815081372100_ref11","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-019-2642-7","article-title":"Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets","volume":"20","author":"Amzallag","year":"2019","journal-title":"BMC Bioinform"},{"key":"2021110815081372100_ref12","article-title":"A Bayesian approach for the study of synergistic interaction effects in in-vitro drug combination experiments","author":"Cremaschi","year":"2019","journal-title":"arXiv"},{"key":"2021110815081372100_ref13","doi-asserted-by":"crossref","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"2021110815081372100_ref14","volume-title":"Gaussian Processes for Machine Learning","author":"Williams","year":"2006"},{"issue":"4","key":"2021110815081372100_ref15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1541-0420.2010.01403.x","article-title":"A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies","volume":"66","author":"Hennessey","year":"2010","journal-title":"Biometrics"},{"key":"2021110815081372100_ref16","doi-asserted-by":"crossref","DOI":"10.1093\/biostatistics\/kxaa047","article-title":"Dose\u2013response modeling in high-throughput cancer drug screenings: an end-to-end approach","author":"Tansey","year":"2021","journal-title":"Biostatistics"},{"issue":"2","key":"2021110815081372100_ref17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"issue":"1","key":"2021110815081372100_ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v076.i01","article-title":"A probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J Stat Softw"},{"key":"2021110815081372100_ref19","volume-title":"RStan: The R Interface to Stan. R package version 2.21.2","author":"Stan Development Team","year":"2020"},{"issue":"47","key":"2021110815081372100_ref20","first-page":"1593","article-title":"The No-U-Turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo","volume":"15","author":"Hoffman","year":"2014","journal-title":"J Mach Learn Res"},{"key":"2021110815081372100_ref21","article-title":"Automatic variational inference in Stan","author":"Kucukelbir","year":"2015"},{"key":"2021110815081372100_ref22","article-title":"Fast hierarchical Gaussian processes","author":"Flaxman","year":"2015"},{"issue":"14","key":"2021110815081372100_ref23","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2009-10-248054","article-title":"Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K\/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia","volume":"116","author":"Shehata","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2021110815081372100_ref24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","article-title":"An unbiased oncology compound screen to identify novel combination strategies","volume":"15","author":"O\u2019Neil","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"D1","key":"2021110815081372100_ref25","article-title":"DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy","volume":"48","author":"Liu","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"430","key":"2021110815081372100_ref26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/01621459.1995.10476572","article-title":"Bayes factors","volume":"90","author":"Kass","year":"1995","journal-title":"J Am Stat Assoc"},{"issue":"10","key":"2021110815081372100_ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v092.i10","article-title":"bridgesampling: an R package for estimating normalizing constants","volume":"92","author":"Gronau","year":"2020","journal-title":"J Stat Softw"},{"issue":"8","key":"2021110815081372100_ref28","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2021110815081372100_ref29","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-scalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021110815081372100_ref30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/onc.2012.84","article-title":"Synthetic lethality of Chk1 inhibition combined with p53 and\/or p21 loss during a DNA damage response in normal and tumor cells","volume":"32","author":"Origanti","year":"2012","journal-title":"Oncogene"},{"key":"2021110815081372100_ref31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60352","article-title":"A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates","volume":"9","author":"Wang","year":"2020","journal-title":"eLife"},{"issue":"1","key":"2021110815081372100_ref32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/msb4100116","article-title":"Chemical combination effects predict connectivity in biological systems","volume":"3","author":"Leh\u00e1r","year":"2007","journal-title":"Mol Syst Biol"},{"issue":"3","key":"2021110815081372100_ref33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2021110815081372100_ref34","doi-asserted-by":"crossref","DOI":"10.1214\/ss\/1177009939","article-title":"Bayesian experimental design: a review","volume":"10","author":"Chaloner","year":"1995","journal-title":"Stat Sci"},{"issue":"11","key":"2021110815081372100_ref35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00204-014-1335-2","article-title":"Optimal experimental designs for dose\u2013response studies with continuous endpoints","volume":"89","author":"Holland-Letz","year":"2014","journal-title":"Arch Toxicol"},{"issue":"1","key":"2021110815081372100_ref36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09799-2","article-title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","volume":"10","author":"Menden","year":"2019","journal-title":"Nat Commun"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab251\/41088270\/bbab251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/22\/6\/bbab251\/41088270\/bbab251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T17:57:18Z","timestamp":1699120638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbab251\/6326504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbab251","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.07.438787","asserted-by":"object"}]},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,7,23]]},"article-number":"bbab251"}}